Le Lézard
Classified in: Health, Science and technology, Business
Subjects: PDT, LIC

Volta Labs and Watchmaker Genomics Partner to Simplify and Optimize NGS Library Prep


BOSTON and BOULDER, Colo., Feb. 5, 2024 /PRNewswire/ -- Volta Labs, a genomics applications company, and Watchmaker Genomics, a supplier of innovative products for molecular analysis, partner to leverage their technologies to power Volta's short-read library prep kits.

Volta Labs and Watchmaker Genomics are jointly committed to making efficient, accessible, and cost-effective library prep a reality. With the launch of Volta's Callistotm Sample Prep System, Watchmaker Genomics will provide the reagents behind various VoltaPreptm library prep kits.

"Volta's digital fluidics technology and their approach to building automated sample prep applications are impressive," said Trey Foskett, CEO of Watchmaker Genomics. "Watchmaker has a passion for delivering superior data quality with simple and automatable workflows. Combining Volta's cutting-edge technology with our innovative reagents delivers in both of these areas, and we look forward to a continued partnership."

"Watchmaker has set the bar high for enzyme engineering and library prep workflow development," said Udayan Umapathi, CEO at Volta Labs. "We are energized to work with their talented team to address quality, cost, and scalability challenges that currently exist in sample prep. This collaboration is the first in a series of Volta applications that will be powered by Watchmaker chemistry."

The Callistotm Sample Prep System offers programmable, precise, and plastic-free liquid manipulation with pre-optimized applications to support short- and long-read sequencing workflows. With a growing menu of library prep kits powered by Watchmaker Genomics' solutions, Volta will continue to expand the universe of pre-optimized applications available through Callisto and enable labs to maximize advancements in sequencing.

About Volta Labs

Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to improve the performance, scalability, and consistency of sample preparation for genomic analyses. Volta Labs is transforming the way new biological protocols are developed, implemented, and executed, allowing scientists to focus on what they do best -- pushing the boundaries of biology.

About Watchmaker Genomics

Watchmaker Genomics applies advanced enzymology to enable breakthrough applications for the reading, writing, and editing of DNA and RNA. The company combines domain expertise in protein engineering with large-scale enzyme manufacturing to address the demanding quality, performance, and scale requirements of high-growth clinical genomics applications. Watchmaker's product portfolio includes enzymes and kits for next-generation sequencing, synthetic biology, and molecular diagnostics. For the latest news and updates, find us on LinkedIn.

Media Contacts:
Jen Pavlica
Watchmaker Genomics
[email protected] 

Kim Miller
Volta Labs
[email protected]

SOURCE Volta Labs Inc.


These press releases may also interest you

at 00:05
Spirit AeroSystems [NYSE: SPR] ("Spirit") today announced it has entered into a definitive merger agreement under which The Boeing Company [NYSE: BA] ("Boeing") will acquire Spirit for $37.25 per share in Boeing common stock (subject to the collar...

at 00:01
Boeing [NYSE: BA] today announced it has entered...

30 jun 2024
Pomelo Group is proud to announce the endorsement of...

30 jun 2024
"AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry." At the 15th Annual Meeting of the New...

30 jun 2024
On June 27, 2024, Yidu Tech Inc. (the ''Company'' or ''Yidu Tech'') (2158.HK), a leader in China's AI medical industry, announced its results for the 2024 fiscal year. During the reporting period, the Company recorded revenue of RMB 807.1 million....

30 jun 2024
Yidu Tech Inc. ("Yidu Tech" or the "Company", together with its subsidiaries and consolidated affiliated entities, the "Group", HKEX: 2158) announced its annual results for the fiscal year ended 31 March 2024 ("FY2024" or the "Reporting Period"). The...



News published on and distributed by: